Clinical trials recruiting for Small Cell Lung Cancer ( SCLC )

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
  NCT06305962 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
  NCT07488923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
  NCT07434518 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
  NCT07465757 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Armored CAR T Cells in People With Cancer
  NCT07783477 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
  NCT07358676 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 84 locations
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  NCT07480213 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  NCT07744256 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
  NCT07149363 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• DLL3-Targeted PET/CT in Small Cell Lung Cancer
  NCT07677787 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
  NCT07517198 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
  NCT05490472 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
  NCT07153055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
  NCT06485544 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
  NCT07510724 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety and Preliminary Activity of BI115 in Advanced SCLC
  NCT07559019 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
  NCT07030257 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
  NCT07339059 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
  NCT07278479 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
  NCT07226999 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 83 locations
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
  NCT07476287 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
  NCT07246304 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• THE-0504 in Patients With Solid Tumors
  NCT07646106 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
  NCT03556228 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 15 locations

Related conditions

Trials recruiting for Small Cell Lung Cancer ( SCLC ) often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Small Cell Lung Cancer ( SCLC ) trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.